Squarepoint
IMNM icon

Squarepoint’s Immunome IMNM Stock Holding History

Squarepoint’s Portfolio IMNM Stock Details IMNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.48M Buy
67,778
+38,445
+131% +$856K ﹤0.01% 2432
2025
Q4 		$630K Buy
+29,333
New +$515K ﹤0.01% 3015
2025
Q1 		– Sell
-17,914
Closed -$190K – 4975
2024
Q4 		$190K Sell
17,914
-13,772
-43% -$166K ﹤0.01% 4489
2024
Q3 		$463K Sell
31,686
-42,243
-57% -$600K ﹤0.01% 3152
2024
Q2 		$895K Sell
73,929
-45,843
-38% -$717K ﹤0.01% 2641
2024
Q1 		$2.96M Buy
+119,772
New +$2.43M 0.01% 1836

Other funds holding IMNM

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return

Squarepoint's IMNM Position: Q1 2026 in Review

Squarepoint increased its Immunome (IMNM) stake by 131% in Q1 2026, buying an estimated $856K and bringing the position to 67,778 shares worth $1.48M. The position accounts for ﹤0.01% of the portfolio, ranked #2432.

Squarepoint first reported a position in IMNM in Q1 2024 and has held it in 6 quarters since. The position peaked at $2.96M in Q1 2024. 200 funds tracked by Wall St. Rank hold IMNM as of Q1 2026.

  • Squarepoint held 67,778 shares of Immunome worth $1.48M as of Q1 2026.
  • Squarepoint bought 38,445 Immunome shares in Q1 2026, an estimated $856K.
  • Immunome made up ﹤0.01% of Squarepoint's portfolio in Q1 2026, its #2432 holding.
  • Squarepoint first reported a position in Immunome in Q1 2024 and has held it in 6 quarters since.
  • Squarepoint's Immunome position peaked at $2.96M in Q1 2024.
  • 200 funds tracked by Wall St. Rank held Immunome as of Q1 2026.

Based on Squarepoint's 13F filing for Q1 2026, filed 15 May 2026.